Reviewing Cabaletta Bio (NASDAQ:CABA) & VectivBio (NASDAQ:VECT)

Cabaletta Bio (NASDAQ:CABA) and VectivBio (NASDAQ:VECT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Profitability

This table compares Cabaletta Bio and VectivBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cabaletta Bio	N/A	-50.10%	-45.49%
VectivBio	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Cabaletta Bio and VectivBio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cabaletta Bio	0	1	6	1	3.00
VectivBio	0	0	0	0	0.00

Cabaletta Bio presently has a consensus target price of $22.71, suggesting a potential upside of 1,108.21%. Given Cabaletta Bio’s stronger consensus rating and higher probable upside, research analysts plainly believe Cabaletta Bio is more favorable than VectivBio.

Risk & Volatility

Cabaletta Bio has a beta of 2.58, meaning that its share price is 158% more volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, meaning that its share price is 89% less volatile than the S&P 500.

Valuation and Earnings

This table compares Cabaletta Bio and VectivBio”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cabaletta Bio	N/A	N/A	-$67.68 million	($2.15)	-0.87
VectivBio	$27.34 million	20.97	-$93.74 million	N/A	N/A

Cabaletta Bio has higher earnings, but lower revenue than VectivBio.

Summary

Cabaletta Bio beats VectivBio on 6 of the 9 factors compared between the two stocks.

About Cabaletta Bio

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.